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Background: Patient dependent parameters to predict the long-term success of early eradication treatment of Pseudomonas aeruginosa have not yet
been deﬁned. For this purpose we assessed serum antibodies against P. aeruginosa in CF patients after early eradication treatment.
Methods: Retrospective analyses of all consecutive patients with ﬁrst P. aeruginosa detection 2005 to 2008. Absence of P. aeruginosa in the third
year was deﬁned as successful long-term eradication. Main outcome was to determine the predictive value of P. aeruginosa antibody results one
year after initiation of early eradication treatment using antibodies against alkaline protease, elastase, and exotoxin A with regard to long-term
success of eradication treatment.
Results: Antibodies against P. aeruginosa correlated well with success of eradication; positive and negative predictive values after one year were 75% and
82% respectively. The incidence of new detection of P. aeruginosa was 8.5%. Long-term eradication was successful in 32 of 53 patients (60%).
Conclusions: Determination of serum antibodies against P. aeruginosa one year after ﬁrst detection of P. aeruginosa and early eradication
treatment can predict success of long-term eradication.
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In cystic fibrosis (CF), Pseudomonas aeruginosa
(P. aeruginosa) is the most frequent respiratory pathogen [1–3]
which is associated with increased morbidity and mortality,
particularly if mucoid forms of P. aeruginosa develop [4,5].
Eradication of P. aeruginosa usually is not possible in the case of
chronic infection [6], but early antibiotic therapy has been shown to
successfully eliminate P. aeruginosa from the respiratory tract of
CF patients [7–13]. Today, early eradication policy is recom-
mended [14,15] and has been implemented in most CF centers.
Despite this general acceptance of the principle of early
eradication treatment, it is not clear which therapeutic regimen
provides the best effect (e.g. the highest rate of eradication) and
which patient-assigned factors might be associated with higher
or lower eradication success. Defining such prognostic factorsll rights reserved.
1 “Double therapy”: inhalative (tobramycin or colistin) plus oral (ciproﬂoxacin).
2 “Mono therapy”: inhalative (tobramycin or colistin) or alternating inhalative/
oral (ciproﬂoxacin).
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specific and target orientated way.
Over the last years, commercialized ELISA antibodies against
P. aeruginosa have been evaluated in different CF populations,
showing a good correlation of antibody titers to chronic infection,
but contradictory findings considering the value of antibody deter-
mination for early diagnosis of P. aeruginosa infection [16–22].
Positive serology has been used to predict treatment failure and the
risk for recurrent P. aeruginosa isolation post eradication [23].
Antibody titer results however, up to now, were not assessed as
surrogate marker to predict long-term success of early eradication
therapy or to define the duration of eradication therapy.
Therefore the aim of our retrospective study was to analyze the
course of serum antibodies against P. aeruginosa in CF patients
after early eradication treatment in correlation to the long-term
success of eradication. The main outcome was the predictive value
of antibodies against P. aeruginosa one year after beginning the
early eradication treatment with regard to its long-term success.
The hypothesis was that the long-term success of a standardized
early eradication treatment would be predictable by using antibody
results one year after initiation of early eradication treatment. The
one year interval was chosen because an early evaluation of serum
antibodies includes the possibility of determining antibodies still
circulating but a later evaluation does not have an impact on
therapeutic eradication efforts. This would offer the possibility to
use the course of antibodies against P. aeruginosa as a tool to
regulate the intensity and duration of antibiotic therapy and thus
improve the efficacy of eradication therapy.
2. Material and methods
2.1. Subjects and study design
From the beginning of 2005, a standardized eradication therapy
protocol was applied in all CF patients from theMunich CF center
in whom P. aeruginosa was detected for the first time in
respiratory samples. These were patients classified as “never
infected” according to the Leeds criteria [24]. All consecutive
patients with first P. aeruginosa detection between January 2005
andDecember 2008 were identified and complete microbiological
and serological results of the following three years were analyzed
retrospectively. The aim of the study was to determine the
predictive value of P. aeruginosa antibody results one year after
initiation of early eradication treatment with regard to long-term
success of eradication therapy as primary outcome. Secondary
outcome parameters were success of the standardized eradication
protocol and the long-term correlation of microbiological results
and serum antibodies after first detection.
2.2. Microbiology and serology
Sputum samples or deep oropharyngeal swabs were routinely
obtained every three months and were cultured on blood-agar
plates and MacConkey-agar-plates for at least 72 h aerobically at
37 °C. After isolation, susceptibility testing was carried out and
confirmation was done using Cetrimide agar and growth at 42 °C.
Patients were classified according to the microbiological resultsobtained in the third year after first detection of P. aeruginosa as
follows: negative (=4 of 4 respiratory samples negative for
P. aeruginosa), intermittent (b2 of 4 respiratory samples positive)
and positive (≥2 of 4 respiratory samples positive). This clas-
sification was used to define the long-term success of eradication
therapy.
Serum antibody titers against the three purified P. aeruginosa
antigens, alkaline protease (AP), elastase (E), and exotoxin A
(EA) were determined annually, using a commercially available
ELISA test system (Mediagnost, Germany) according to the
manufacturer's instructions as described before [18]. The antibody
titers were expressed in arbitrary units and were categorized as 0
(titer negative b1:500), and 1 (titer positive ≥1:500). The scores
of the three antibodies were pooled as cumulative score (giving
values between 0 and 3). The cumulative score was defined
negative if none of the antibodies was≥1:500 and positive if any
of the antibodies was ≥1:500. In case of more than one
determination of antibodies per year, mean annual scores were
calculated. “Annual” in this context (microbiology and serology)
is referring to the point in time, when P. aeruginosa was firstly
detected in a patient, starting the first, second, or third year after
first detection. For the calculation of predictive values (primary
outcome), the results of a single antibody determination one year
after first detection of P. aeruginosa were used to classify the
antibody status as negative (no titer ≥1:500 in any antibody
determination) or positive (any titer ≥1:500).
2.3. Standardized eradication therapy protocol
In case of P. aeruginosa detection in respiratory samples the
following early eradication treatment was initiated immediately
after notification by the microbiological laboratory according to
antibiotic susceptibility if appropriate:
Three weeks “double therapy”1 followed by one year “mono
therapy”.2
In case of a new detection of P. aeruginosa:
Three months “double therapy”1 followed by one year
“mono therapy”.2
In any case of a new detection of P. aeruginosa:
Additional three weeks intravenous therapy with two
antibiotics active according to resistance.
Used dosages:
Inhalative: Tobramycin 300 mg in 5 ml twice a day, colistin
33 mg in 3 ml twice a day. Inhalation device Pari eflow in
patients 10 years or older and Pari SX in patients younger
than 10 years using the LC plus nebulizer.
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Intravenous (all in two daily doses): Ceftazidime 150 mg/kg,
tobramycin 7 mg/kg, meropenem 60 mg/kg, colistin 2.5 mg/kg,
fosfomycin 250 mg/kg, and piperacillin/tazobactam 225 mg/kg.2.4. Statistical analysis
Sensitivity, specificity, 95% confidence intervals (95% CI),
positive predictive values (PPV) and negative predictive values
(NPV) were calculated from contingency tables; with confi-
dence intervals calculated using the binominal exact method.
As variable 1, the result of antibody testing one year after first
detection of P. aeruginosa, scored as negative or positive
as described above was used. As variable 2, the long-term
success of standard early eradication treatment, defined as
Pseudomonas-status within the third year after first detection of
P. aeruginosa was used. For the calculation of the predictive
values, the prevalence of unsuccessful eradication (definition:
≥1 microbiological detection of P. aeruginosa in the third
year after first detection) was used as given in our cohort (21 of
53 = 40%). For comparison of unrelated data the Mann–
Whitney Test was used, for categorical variables the Fisher's
Exact Test was applied. Analyses were performed using SPSS
version 12.0 for Windows (SPSS Inc., Chicago, IL). Data are
given as mean (median, range).
Informed consent was obtained from all subjects. The study
has been approved by the local institutional review board for
human studies of the University Children's Hospital, Munich.
3. Results
3.1. Subjects, susceptibility, and incidence
Between January 2005 and December 2008, 58 CF patients
so far never infected according to the Leeds criteria [24] were
identified in whom P. aeruginosa was detected in respiratory
samples for the first time (swab: n = 54, sputum: n = 4). The
mean age of these patients was 8.4 years, range 0.4 to 25.9,
male n = 30, mean FEV1 (% pred.) 93.9. As expectable, these
subjects were younger than the complete Munich CF collective
(370 CF patients, mean age 17.1 years, range 0.1 to 43, mean
FEV1 (% pred.) 88.6) because P. aeruginosa free patients in
the Munich collective in general were younger (71% of patients
were P. aeruginosa free in the age group b18 years and only
12% in the age group N18 years).
These first isolates of P. aeruginosa demonstrated complete
susceptibility to standard antibiotics (ceftazidime, tobramycin,
meropenem, colistin, fosfomycin, ciprofloxacin, piperacillin/
tazobactam) in 70% (n = 37) and resistance to ≥ 1 antibiotic in
30% (n = 16).
Taking the total number of P. aeruginosa free patients in
the Munich CF center (n = 170) and the new detection of
P. aeruginosa in the study period (n = 58), the incidence of
new detection of P. aeruginosa was calculated as 34% for the
four year study period and correspondingly 8.5% per year in
our patient population.Five of these 58 patients were lost to follow-up within the
first year after first detection of P. aeruginosa and 53 of
these 58 patients attended the Munich CF center permanently
over the three year period following the first detection of
P. aeruginosa and were subject for further analysis.
3.2. Data identification
In 40 of the 53 patients long-term data following first
detection of P. aeruginosa were without gap (≥4 microbio-
logical results from respiratory samples per year and ≥1 result
of determination of serum antibodies against P. aeruginosa
for each of the three years following the first detection of
P. aeruginosa). These subjects were included in the long-term
analysis, the “per protocol” (PP) analysis. In the remaining 13
patients with fragmentary data, results of antibody determina-
tion one year after first detection and ≥2 microbiological
results within the third year after first detection were available
and these patients were additionally included in the primary
outcome analysis considering predictive values, the “intention
to treat” (ITT) analysis (Fig. 1).
3.3. The course of serum antibodies against P. aeruginosa over
three years after first detection of P. aeruginosa correlates to
the eradication success
Complete data were available in 40 patients (PP analysis).
Standard early eradication treatment was successful in 25 (62.5%)
of these 40 patients, defined as 0 of ≥4 microbiological detec-
tion of P. aeruginosa in the third year after first detection of
P. aeruginosa. It was not successful in 5 patients (≥50% of
P. aeruginosa detection within the third year, classified as chronic
infection) and was marginally successful in 10 patients (b50% of
P. aeruginosa detection within the third year, classified as
intermittent infection). Neither antibiotic susceptibility (p = 0.22,
Fisher's Exact Test) nor positive titers at baseline (p = 0.19,
Mann–Whitney Test) did influence the success rate of eradication.
In patients in whom eradication was successful (n = 25), the
P. aeruginosa antibody scores did not rise, in patients in whom
eradication was not (n = 5) or partially successful (n = 10), the
P. aeruginosa antibody scores increased clearly, as shown in
Fig. 2. In years two and three after first detection of P. aeruginosa
these differences were statistically significant whereby the course
of antibodies differentiated well between successful and not
successful eradications.
3.4. Predictive values one year after initiation of eradication
therapy
To determine the predictive value of P. aeruginosa antibody
results one year after initiation of early eradication treatment,
data of 53 patients were analyzed (ITT analysis). Eradication
therapy was successful in 32 of these 53 patients (60%) and not
successful in 21 of 53 patients (intermittent infection: n = 10,
chronic infection: n = 11). Predictive values were calculated
from contingency tables with confidence intervals calculated
Fig. 1. Subjects included. Between January 2005 and December 2008, P. aeruginosa was newly detected in 58 CF patients (incidence 8.5%). In 53 of these
microbiological and serological data allowed further analysis considering the primary outcome “predictive values”. According to microbiological results in the
third year after first detection, patients were allocated to “eradication successful” (n = 32, no P. aeruginosa detection in the third year) or “eradication not successful”
(n = 21, any P. aeruginosa detection in the third year), the latter differentiated as “intermittent infection” (n = 10) and chronic infection (n = 11).
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cumulative scores are shown in Table 1.
One year after first detection of P. aeruginosa, in the suc-
cessfully eradicated patients, the mean cumulative Pseudomonas
antibody score was 0.19 whereas in the not successfully eradicatedpatients (intermittent and chronic infections) the mean cumulative
Pseudomonas antibody score was 1.4.
Considering cumulative scores, of the 32 patients in whom
eradication was successful, 27 had a negative antibody score
and 5 patients had a positive score. Of the 21 patients in
Fig. 2. The course of antibodies after eradication therapy correlates with the success of eradication therapy. Complete long-term data of 40 patients were available.
Microbiological results (bars) and mean cumulative annual antibody scores (lines) in CF patients before and after standard early eradication therapy. White bar: free of
P. aeruginosa. Shaded bar: intermittent infection. Black bar: chronic infection (classification according to ≥4 microbiological results obtained in the third year after
first P. aeruginosa detection). Long-term antibody scores stay low in patients free of P. aeruginosa (A) and rise in patients with intermittent infection (B) and patients
with chronic infection (C). *p b 0.05 in Mann–Whitney Test for comparison of antibody scores. Baseline serology: positive antibodies before first microbiological
detection of P. aeruginosa: negative n = 2 (8%), intermittent n = 1 (10%) and chronic n = 2 (40%). Long-term serology: positive antibodies “year 3” after detection:
negative n = 2 (8%), intermittent n = 6 (60%) and chronic n = 4 (80%).
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(chronic 10 of 11, intermittent 5 of 10) and 6 had a negative
score (p = 0.004, Fisher's Exact Test). A positive cumulative
antibody score one year after first detection predicted chronic or
intermittent infection with a probability of 75% [95% CI: 51–
91], if the antibody score against elastase was positive, thepositive predictive value was 91% [95% CI: 59–99]. A
negative cumulative antibody score one year after first
detection predicted successful eradication with a probability
of 82% [95% CI: 65–93] (see Table 2 for the results of
contingency tables). An additional “per protocol analysis” of
predictive values of the cumulative antibody score one year
Table 1
Antibodies against Pseudomonas aeruginosa one year after first detection in correlation to Pseudomonas status according to microbiological results obtained within
the third year after first detection.
Negative Intermittent & positive Intermittent Positive
N = 32 N = 21 N = 10 N = 11
AP
(alkaline protease)
Inverse titer (mean, SD) 162 ± 340 1295 ± 1662 399 ± 693 2110 ± 1887
Score (mean) 0.06 0.4 0.1 0.7
% positive score 6 43 10 73
E
(elastase)
Inverse titer (mean, SD) 75 ± 174 1406 ± 2250 198 ± 559 2503 ± 2658
Score (mean) 0.04 0.5 0.1 0.8
% positive score 4 52 10 80
EA
(exotoxin A)
Inverse titer (mean, SD) 208 ± 421 1216 ± 1530 629 ± 901 1750 ± 1815
Score (mean) 0.09 0.5 0.4 0.6
% positive score 9 52 40 64
Cumulative Score (mean) 0.19 1.4 0.6 2.2
% positive score (N1) 16 71 50 91
Negative (n = 32), intermittent (n = 10), and positive (n = 11).
SD: standard deviation.
Antibodies against P. aeruginosa: AP: alkaline protease, E: elastase, EA: exotoxin A.
For AP, E, and EA: negative score = 0: titer b 1:500, positive score = 1: titer ≥ 1:500.
For cumulative score: negative score = 0: titer of AP, E, and EA negative, score = 1, 2, 3: 1, 2, 3 positive titers.
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complete long-term data produced almost identical results:
positive predictive value 75% [95% CI: 59–92] and negative
predictive value 79% [95% CI: 65–93].
For explorative purpose, a calculation of predictive values
using a combination of antibody determination with microbi-
ological results was performed. As variable 1, two results were
combined: antibody status one year after first detection of
P. aeruginosa and microbiological detection of P. aeruginosa
within the first year (positive = positive antibody status and
detection of P. aeruginosa, negative = negative antibody status
and/or no detection of P. aeruginosa). As variable 2, the
long-term success of standard early eradication treatment wasTable 2
Results of contingency tables with predictive values.
AP E EA Cumulative
Sensitivity (%) [CI] 43 [22–66] 48 [26–70] 52 [30–74] 71 [48–89]
Specificity (%) [CI] 94 [79–99] 97 [84–99] 90 [75–98] 84 [67–95]
Positive predictive
value (%) [CI]
82 [48–97] 91 [59–99] 79 [49–95] 75 [51–91]
Negative predictive
value (%) [CI]
71 [55–84] 74 [58–86] 74 [58–87] 82 [65–93]
Variable 1: negative or positive antibody status one year after first detection of
P. aeruginosa. Negative = titer b 1:500, positive = titer ≥ 1:500. For cumu-
lative score: negative = all titers of AP, E, and EA negative, positive = any of
AP, E, and EA titers positive.
Variable 2: Pseudomonas-status defined according to microbiological results
obtained within the third year after first detection of P. aeruginosa. Negative =
no P. aeruginosa, positive = any P. aeruginosa detection in the third year.
(Underlying data are given in Table 1.)
For the calculation of predictive values, the prevalence of unsuccessful
eradication (definition: ≥1 microbiological detection of P. aeruginosa in the
third year after first detection) was used as given in our cohort.
Antibody score against P. aeruginosa: AP = alkaline protease, E = elastase and
EA = exotoxin A.
[CI] = 95% confidence interval, using the binominal exact method.used as described above. This approach did not improve the
predictive values (data not shown).
Interestingly, of the intermittently infected patients (n = 10)
after a longer period of observation, in the fifth year after first
detection, 6 patients still were intermittently infected (antibody
after one year positive n = 3, negative n = 3), two were defined
as chronically infected, both were positive for antibodies after
one year, and two were defined as negative, both were negative
for antibodies after one year. Of the chronically infected
patients as defined by cultural results of the third year (n = 11),
only one patient had negative antibody results; this patient
turned out to have a transient reduction of immunoglobulin
G (IgG) serum levels during the study (values between 265 and
423 mg/dl).
4. Discussion
Here we demonstrate that P. aeruginosa antibodies at an
early stage of infection (one year after first detection) predict
the long-term success of early eradication treatment. Our results
further show that the long-term course of serum antibodies
against P. aeruginosa in our clinical setting and patient cohort
correlates very well to the success of early eradication treatment
in CF patients previously never colonized with P. aeruginosa.
In a clinical setting with non-expectorating patients, nega-
tive microbiological results during early eradication treatment
do not reliably indicate success of eradication therapy due to
the limited validity of “non-lavage” specimens (deep oropha-
ryngeal swab) [25] although it was shown recently that
bronchoalveolar lavage-directed therapy did not result in a
lower prevalence of P. aeruginosa infection compared with
standard therapy [26]. Furthermore these specimens may be
falsely negative if obtained during antibiotic therapy with high
antibiotic levels in the swab region from inhalative therapy. As
a result, early eradication treatment usually is applied for
predefined time-periods and not based on (possibly unreliable)
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eradication treatment is 12 months (see Material and methods).
As there is insufficient evidence to state which antibiotic strategy
for what time-period should be used for the best eradication of
early P. aeruginosa infection in CF [27], another parameter to
indicate the effectiveness of eradication therapy would be very
useful. This question was partly addressed in a recent publication
by Anstead et al. including data from 304 CF patients after
eradication therapy [23]. The point in time when eradication
success was defined was very early in this study (10 weeks) and
thus a longitudinal analysis was not possible. However, serum
antibodies directed against P. aeruginosa, according to our results,
allow a prognosis concerning the long-term success of eradication
therapy at an early stage of infection as the determination of
eradication success is postponed to the third year after eradication.
This suggests that antibody determinations in the future may be
used to decide if antibiotic therapy should be continued beyond a
predefined period of antibiotic treatment in an individual patient.
A similar conclusion was drawn by Anstead et al. [23] who
reported that positive titers against alkaline protease and exotoxin
Awere significantly associated with a higher risk of P. aeruginosa
re-isolation following early eradication treatment. They concluded
that CF patients with new acquisition of P. aeruginosa and
positive serology may benefit from closer monitoring, enhancing
the ability to quickly treat recurrent infection. Similarly Dolce et
al. reported that an increase in antibody titers 6 months after early
eradication treatment was associated with successive isolation of
P. aeruginosa which was interpreted as a possible alarm for
treatment failure [28]. In both studies the point in time after early
eradication treatment to define the serological status was earlier
than in our study. We defined a 12 month interval in order to
i) allow circulating antibodies to decline in case of successful
treatment and ii) to support clinical decision making at the end of
our eradication treatment (12 month period). The success of such
an approach needs to be evaluated prospectively in a randomized
controlled trial.
Apparently a success rate of 60% eradication in our cohort was
not very good compared to recent publications reporting higher
success rates up to 93% [8–10,12,13,29,30]. However, all these
reports are not directly comparable for various reasons. First, the
antibiotic treatment varies between 12 months (Ratjen et al. [9]
andWiesemann et al. [13]) and only 1 month (Taccetti et al. [11]).
Second, and more importantly, the point in time after initiation of
eradication therapy when success of eradication is determined
differs widely in these studies. It is two years in the reports by
Griese et al. [8] and Ratjen et al. [9] but only 6 months in the study
reported by Taccetti et al. [11] and even directly after the end of
antibiotic therapy in the study reported by Proesmans et al. [29]. In
the study presented here however, the Pseudomonas status was
defined according to microbiological results obtained in the third
year after first detection of P. aeruginosa. This long time period
was chosen in order to reliably judge the long-term success of
eradication therapy, which, from a clinical point of view is
“Pseudomonas free after eradication” and not “significant fewer
Pseudomonas detections in respiratory samples after eradication”,
often falsely used as a synonym. Accordingly, we did not dis-
tinguish between chronic and intermittent infections to calculatepredictive values. Counting only chronic infection as an
unsuccessful eradication, we would have a success rate of 79%,
thereby being in accordance with other studies.
Since we did not use molecular typing of P. aeruginosa in our
microbiological routine, as a limitation of our study, we cannot
differentiate between unsuccessful eradication and new acquisi-
tion of P. aeruginosa infections in patients eradicated successful-
ly. The retrospective character of our single center study design
and the relatively small number of subjects included are further
limitations of the current study and conclusions must be
drawn carefully. However, the fundamental correlation between
long-term eradication success and P. aeruginosa antibodies has
clearly been shown for the cohort of the CF patients included.
Results of antibody determination in an early course of infection
might help to select different eradication protocols in order to
adapt eradication strategy individually. Defining an individual
eradication treatment strategy according to P. aeruginosa
antibodies is a major clinical goal due to the burden of therapy
and potential toxicity of eradication therapy.
In conclusion, the long-term course of the analyzed serum
antibodies directed against P. aeruginosa correlates well with
the success of early eradication treatment. A single antibody
determination at an early stage of infection, e.g. one year after
first detection of P. aeruginosa, is meaningful as indicated by
the usable predictive values and might lead to individualized
eradication therapy in the future.Competing interest
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